TH€ PUNT: Key hiring for United Drug
IRISH pharmaceutical services company United Drug has appointed a new board member.
American Lisa Ricciardi, who has an MBA from the University of Chicago, joins as a non-executive director of the Irish company whose interests range from drug distribution to marketing and packaging.
A veteran of the pharmaceuticals industry, she is the newest addition to a board that boasts some impressive names.
These include Smurfit Kappa chief executive Gary McGann, former Kerry Group chief executive Hugh Friel, as well as Chris Brinsmead, the former Astra Zeneca chairman and president of The Association of the British Pharmaceutical Industry.
Ms Ricciardi's appointment is particularly welcome given that United Drug's board members are currently all men. Her experience is impressive, including a 19-year stint with Pfizer in licensing and development and, most recently, a two-year position in business development at Medco Health Solutions.
According to Ms Ricciardi she increased new leads at Prizer by 50pc and completed 25-plus deals with an estimated value of $300m to $7bn at the company, as well as being hand-picked to launch major arthritis drug Tenidap.
She will join United Drug's risk, acquisitions and finance committee, which makes sense given that she was also previously a venture partner with New York private equity company Essex Woodlands.
Ms Ricciardi's American citizenship makes her an even more attractive addition to United Drug. The US became the company's largest profit-contributing region in the first half of this year.